Pfizer, the US pharmaceuticals giant, has appointed long-standing adviser Lazard to explore strategic options for its consumer healthcare business, valued by one analyst at $10bn (€8.4bn).

A spokesman for Lazard confirmed the bank had been appointed. Pfizer was not immediately available for comment.